In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


LiPlasome Pharma AS

Latest From LiPlasome Pharma AS

Clavis Pharma AS

Norwegian biotechnology company Clavis Pharma was spun out of Norsk Hydro in August 2001 to commercialize Lipid Vector Technology (LVT). LVT conjugates fatty acids to existing therapeutics to improve their ability to enter target cells. Clavis' first product is an LVT derivative of Ara-C, a common chemotherapy for blood cancers, which the firm is testing in solid tumor indications.
BioPharmaceutical Europe

LiPlasome Pharma AS

LiPlasome Pharma AS was established in January 2001 to commercialize its novel lipid-based drug delivery platform based on engineered liposomes dubbed liplasomes. LiPlasome is applying its technology to the oncology arena, to both improve upon existing drugs' safety and efficacy and to develop novel lipid-based compounds.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Denmark
  • Parent & Subsidiaries
  • LiPlasome Pharma AS
  • Senior Management
  • Kent Jorgensen, PhD, CEO
  • Contact Info
  • LiPlasome Pharma AS
    Phone: (45) 45252458
    Technical University of Denmark
    Bldg. 207
    Lyngby, 2800